Triggering regeneration and tackling apoptosis: A combinatorial approach to treating congenital muscular dystrophy type 1 A

Human Molecular Genetics

Volumn 22, Issue 21, 2013, Pages 4306-4317

  Yamauchi, Jenny ^a   Kumar, Ajay ^a   Duarte, Lina ^a   Mehuron, Thomas ^a   Girgenrath, Mahasweta ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; CREATINE KINASE; MECASERMIN RINFABATE; PROTEIN BAX; SOMATOMEDIN C;

ANIMAL MODEL; APOPTOSIS; ARTICLE; BODY WEIGHT; CELL REGENERATION; CONGENITAL MUSCULAR DYSTROPHY TYPE 1 A; CREATINE KINASE BLOOD LEVEL; FIBROSIS; GENE OVEREXPRESSION; INFLAMMATION; LOCOMOTION; MOUSE; MUSCLE FUNCTION; MUSCLE MASS; MUSCULAR DYSTROPHY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BODY WEIGHT; COMBINED MODALITY THERAPY; GENE EXPRESSION REGULATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LAMIN TYPE A; LAMININ; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR NEURONS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, ANIMAL; PHENOTYPE; REGENERATION; TREATMENT OUTCOME;

EID: 84885769731     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt280     Document Type: Article

References (44)

1. Muntoni, F. and Voit, T. (2004) The congenital muscular dystrophies in 2004: a century of exciting progress. Neuromuscul. Disord., 14, 635-649.
2. Philpot, J., Bagnall, A., King, C., Dubowitz, V. and Muntoni, F. (1999) Feeding problems in merosin deficient congenital muscular dystrophy. Arch. Dis. Child., 80, 542-547.
3. Philpot, J., Cowan, F., Pennock, J., Sewry, C., Dubowitz, V., Bydder, G. and Muntoni, F. (1999) Merosin-deficient congenital muscular dystrophy: the spectrum of brain involvement on magnetic resonance imaging. Neuromuscul. Disord., 9, 81-85.
4. Colognato, H. and Yurchenco, P.D. (2000) Form and function: the laminin family of heterotrimers. Dev. Dyn., 218, 213-234.
5. Burkin, D.J. and Kaufman, S.J. (1999) The alpha7beta1 integrin in muscle development and disease. Cell Tissue Res., 296, 183-190.
6. Kuang, W., Xu, H., Vachon, P.H. and Engvall, E. (1998) Disruption of the lama2 gene in embryonic stem cells: laminin alpha 2 is necessary for sustenance of mature muscle cells. Exp. Cell Res., 241, 117-125.
7. Guo, L.T., Zhang, X.U., Kuang, W., Xu, H., Liu, L.A., Vilquin, J.T., Miyagoe-Suzuki, Y., Takeda, S., Ruegg, M.A., Wewer, U.M. et al. (2003) Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscul. Disord., 13, 207-215.
8. Miyagoe, Y., Hanaoka, K., Nonaka, I., Hayasaka, M., Nabeshima, Y., Arahata, K. and Takeda, S. (1997) Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy. FEBS Lett., 415, 33-39.
9. Arahata, K. and Engel, A.G. (1984) Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann. Neurol., 16, 193-208.
10. Kuang, W., Xu, H., Vilquin, J.T. and Engvall, E. (1999) Activation of the lama2 gene in muscle regeneration: abortive regeneration in laminin alpha2-deficiency. Lab Invest., 79, 1601-1613.
11. Hayashi, Y.K., Tezak, Z., Momoi, T., Nonaka, I., Garcia, C.A., Hoffman, E.P. and Arahata, K. (2001) Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul. Disord., 11, 350-359.
12. Vachon, P.H., Loechel, F., Xu, H., Wewer, U.M. and Engvall, E. (1996) Merosin and laminin in myogenesis; specific requirement for merosin in myotube stability and survival. J. Cell Biol., 134, 1483-1497.
13. Spencer, M.J. and Tidball, J.G. (2001) Do immune cells promote the pathology of dystrophin-deficient myopathies? Neuromuscul. Disord., 11, 556-564.
14. Moll, J., Barzaghi, P., Lin, S., Bezakova, G., Lochmuller, H., Engvall, E., Muller, U. and Ruegg, M.A. (2001) An agrin minigene rescues dystrophic symptoms in a mousemodel for congenital muscular dystrophy. Nature, 413, 302-307.
15. Gawlik, K.I., Li, J.Y., Petersen, A. and Durbeej, M. (2006) Laminin alpha1 chain improves laminin alpha2 chain deficient peripheral neuropathy. Hum. Mol. Genet., 15, 2690-2700.
16. Gawlik, K.I., Mayer, U., Blomberg, K., Sonnenberg, A., Ekblom, P. and Durbeej, M. (2006) Laminin alpha1 chain mediated reduction of laminin alpha2 chain deficient muscular dystrophy involves integrin alpha7beta1 and dystroglycan. FEBS Lett., 580, 1759-1765.
17. Engvall, E. and Wewer, U.M. (2003) The newfrontier in muscular dystrophy research: booster genes. FASEB J., 17, 1579-1584.
18. Carmignac, V., Svensson, M., Korner, Z., Elowsson, L., Matsumura, C., Gawlik, K.I., Allamand, V. and Durbeej, M. (2011) Autophagy is increased in laminin alpha2 chain-deficient muscle and its inhibition improves muscle morphology in a mouse model of MDC1A. Hum. Mol. Genet., 20, 4891-4902.
19. Elbaz, M., Yanay, N., Aga-Mizrachi, S., Brunschwig, Z., Kassis, I., Ettinger, K., Barak, V. and Nevo, Y. (2012) Losartan, a therapeutic candidate in congenital muscular dystrophy: studies in the dy(2J)/dy(2J) mouse. Ann. Neurol., 71, 699-708.
20. Borner, C. (2003) The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol. Immunol., 39, 615-647.
21. Girgenrath, M., Dominov, J.A., Kostek, C.A. and Miller, J.B. (2004) Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy. J. Clin. Invest., 114, 1635-1639.
22. Kumar, A., Yamauchi, J., Girgenrath, T. and Girgenrath, M. (2011) Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A. Hum. Mol. Genet., 20, 2333-2343.
23. Schrijvers, D.M., De Meyer, G.R., Herman, A.G. and Martinet, W. (2007) Phagocytosis in atherosclerosis: Molecular mechanisms and implications for plaque progression and stability. Cardiovasc. Res., 73, 470-480.
24. Canbay, A., Friedman, S. and Gores, G.J. (2004) Apoptosis: the nexus of liver injury and fibrosis. Hepatology, 39, 273-278.
25. Demedts, I.K., Demoor, T., Bracke, K.R., Joos, G.F. and Brusselle, G.G. (2006) Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema. Respir. Res., 7, 53.
26. Bittner, R.E., Anderson, L.V., Burkhardt, E., Bashir, R., Vafiadaki, E., Ivanova, S., Raffelsberger, T., Maerk, I., Hoger, H., Jung, M. et al. (1999) Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nat. Genet., 23, 141-142.
27. Nakagawa, M., Miyagoe-Suzuki, Y., Ikezoe, K., Miyata, Y., Nonaka, I., Harii, K. and Takeda, S. (2001) Schwann cell myelination occurred without basal lamina formation in laminin alpha2 chain-null mutant (dy3 K/dy3 K) mice. Glia, 35, 101-110.
28. Homma, S., Beermann, M.L. and Miller, J.B. (2011) Peripheral nerve pathology, including aberrant Schwann cell differentiation, is ameliorated by doxycycline in a laminin-alpha2-deficient mouse model of congenital muscular dystrophy. Hum. Mol. Genet., 20, 2662-2672.
29. Girgenrath, M., Beermann, M.L., Vishnudas, V.K., Homma, S. and Miller, J.B. (2009) Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy. Ann. Neurol., 65, 47-56.
30. Briguet, A., Courdier-Fruh, I., Foster, M., Meier, T. and Magyar, J.P. (2004) Histological parameters for the quantitative assessment of muscular dystrophy in the mdx-mouse. Neuromuscul. Disord., 14, 675-682.
31. Allamand, V. and Guicheney, P. (2002) Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin). Eur. J. Hum. Genet., 10, 91-94.
32. Meinen, S., Lin, S., Thurnherr, R., Erb, M., Meier, T. and Ruegg, M.A. (2011) Apoptosis inhibitors and mini-agrin have additive benefits in congenital muscular dystrophy mice. EMBO Mol. Med., 3, 465-479.
33. Balaram, S.K., Agrawal, D.K. and Edwards, J.D. (1999) Insulin like growth factor-1 activates nuclear factor-kappaB and increases transcription of the intercellular adhesion molecule-1 gene in endothelial cells. Cardiovasc. Surg., 7, 91-97.
34. Adler, A.S., Sinha, S., Kawahara, T.L., Zhang, J.Y., Segal, E. and Chang, H.Y. (2007) Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev., 21, 3244-3257.
35. Salminen, A. and Kaarniranta, K. (2009) NF-kappaB signaling in the aging process. J. Clin. Immunol., 29, 397-405.
36. Salminen, A., Huuskonen, J., Ojala, J., Kauppinen, A., Kaarniranta, K. and Suuronen, T. (2008) Activation of innate immunity system during aging: NF-kBsignaling is the molecular culprit of inflamm-aging. Ageing Res. Rev., 7, 83-105.
37. Dela Pena, A., Leclercq, I., Field, J., George, J., Jones, B. and Farrell, G. (2005) NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology, 129, 1663-1674.
38. Marcolin, E., San-Miguel, B., Vallejo, D., Tieppo, J., Marroni, N., Gonzalez-Gallego, J. and Tunon, M.J. (2012) Quercetin treatment ameliorates inflammation and fibrosis in mice with nonalcoholic steatohepatitis. J. Nutr., 142, 1821-1828.
39. Sunada, Y., Bernier, S.M., Utani, A., Yamada, Y. and Campbell, K.P. (1995) Identification of a novel mutant transcript of laminin alpha 2 chain gene responsible for muscular dystrophy and dysmyelination in dy2J mice. Hum. Mol. Genet., 4, 1055-1061.
40. Di Muzio, A., De Angelis, M.V., Di Fulvio, P., Ratti, A., Pizzuti, A., Stuppia, L., Gambi, D. and Uncini, A. (2003) Dysmyelinating sensory-motor neuropathy in merosin-deficient congenital muscular dystrophy. Muscle Nerve, 27, 500-506.
41. Shorer, Z., Philpot, J., Muntoni, F., Sewry, C. and Dubowitz, V. (1995) Demyelinating peripheral neuropathy in merosin-deficient congenital muscular dystrophy. J. Child. Neurol., 10, 472-475.
42. Heatwole, C.R., Eichinger, K.J., Friedman, D.I., Hilbert, J.E., Jackson, C.E., Logigian, E.L., Martens, W.B., McDermott, M.P., Pandya, S.K., Quinn, C. et al. (2011) Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch. Neurol., 68, 37-44.
43. Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G., Molinaro, M., Barton, E.R., Sweeney, H.L. and Rosenthal, N. (2001) Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet., 27, 195-200.
44. Knudson, C.M., Tung, K.S., Tourtellotte, W.G., Brown, G.A. and Korsmeyer, S.J. (1995) Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science, 270, 96-99.